ERBB2 and breast cancer: Paoletti et al. [84] described a study with 45 estrogen receptor-positive (ER)/HER2-negative metastatic or locoregionally recurrent disease BC patients enrolled in the CTC analysis, but only 11 presented ≥5 CTCs.